AI assistant
Sending…
Nuvectis Pharma, Inc. — Director's Dealing 2022
Nov 18, 2022
33912_dirs_2022-11-18_f9c5aac6-cd3f-485f-85b0-2355abc85a34.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Nuvectis Pharma, Inc. (NVCT)
CIK: 0001875558
Period of Report: 2022-11-16
Reporting Person: Shemesh Shay (Chief Dev. & Ops. Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-11-16 | Common Stock | P | 150 | $7.10 | Acquired | 1245215 | Direct |
| 2022-11-17 | Common Stock | P | 150 | $7.20 | Acquired | 1245365 | Direct |
Footnotes
F1: Includes 48,399 shares of restricted stock and 60,000 restricted stock units.
More from Nuvectis Pharma, Inc.
Interim / Quarterly Report
2026
May 5
Earnings Release
2026
May 5
Regulatory Filings
2026
Feb 23
Capital/Financing Update
2026
Feb 13
Earnings Release
2026
Feb 11
Annual Report
2026
Feb 11
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9